title: Salivary anticandidal activity and saliva composition in an HIV-infected cohort.
abstract: This study investigated salivary anticandidal activity and salivary composition in stimulated whole saliva of 18 advanced HIV-infected patients and compared these values to healthy controls. Stimulated whole saliva from HIV-infected patients showed decreased anticandidal activity. The flow rate was reduced by 40% as compared with controls. The saliva flow rate for HIV-infected patients who had recoverable yeast in their saliva was reduced as compared to HIV-infected patients without recoverable yeast. For HIV-infected patients, the saliva concentrations of lactoferrin, secretory IgA and Cl- were increased while the secretion rate of lysozyme, total protein and K+ were reduced. There was no difference in any parameter as a function of taking the antifungal drug fluconazole. There was no association between salivary anticandidal activity and any salivary component. This study shows reduced anticandidal activity and salivary flow rate in HIV-infected patients. These alterations may contribute to their increased incidence of oral candidal infections.
authors.affiliation: Department of Dental Diagnostic Science, University of Texas Health Science Center at San Antonio, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Lin
authors.forename: D A
authors.initials: DA
authors.lastname: Johnson
authors.forename: T F
authors.initials: TF
authors.lastname: Patterson
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: D L
authors.initials: DL
authors.lastname: Lu
authors.forename: Q
authors.initials: Q
authors.lastname: Shi
authors.forename: C K
authors.initials: CK
authors.lastname: Yeh
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects / Q000276:immunology; D002180:Candidiasis, Oral / Q000150:complications / Q000276:immunology*; D016022:Case-Control Studies; D015331:Cohort Studies; D015169:Colony Count, Microbial; D004573:Electrolytes / Q000032:analysis; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D056229:Fungal Structures; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012463:Saliva / Q000737:chemistry / Q000378:metabolism / Q000382:microbiology / Q000502:physiology*; D012471:Salivary Proteins and Peptides / Q000032:analysis; D012636:Secretory Rate
chemical_list: D000935:Antifungal Agents; D004573:Electrolytes; D012471:Salivary Proteins and Peptides; D015725:Fluconazole